Systematic Review and Meta-Analysis on Dapagliflozin and Anemia in CKD

Eight studies from six databases were synthesized to evaluate the drug dapagliflozin's effect on anemia in chronic kidney disease patients. The meta-analysis, performed according to PRISMA guidelines, found a significant mean difference in hemoglobin of 4.37 and a reduction in adverse event risk. This document, authored by Annida Naufal Irvania and updated in April 2026, presents the full review and analysis.

Use Cases

• Assessing the efficacy of dapagliflozin for improving hemoglobin levels based on the pooled analysis results.
• Evaluating the safety profile of dapagliflozin for CKD patients based on the reported adverse event and mortality risk ratios.
• Informing the design of future clinical trials for anemia treatments based on the identified evidence gaps and conclusions.

Strengths

• Follows PRISMA guidelines for systematic review and meta-analysis methodology.
• Includes risk-of-bias assessment using tools like RoB 2, NOS, and JBI.
• Data were pooled using a random-effects model with RevMan 5.4 software.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The underlying primary studies and their specific patient populations are not detailed in this metadata.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of eight identified studies.

Time Range

null

Freshness

Last updated 2026-04-23 07:57:17; freshness should be verified.

Geography

null